Stock2Me’s latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms. To begin the interview, Bunka provided a summary of Lexaria’s business model, which is focused on leveraging the company’s proprietary DehydraTECH™ drug delivery technology. “[Lexaria has] developed a drug delivery technology that’s quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we’re so good at it, we’re actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent’ our technology.”